Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032141 | 1.00 | APP (1.00) | APPGLAGAASULT1A1 | |
| SCHEMBL13853554 | 0.97 | APP (0.95) | APPGLAGAASULT1A1 | |
| SCHEMBL1984302 | 0.93 | APP (0.86) | APPGLAGAASULT1A1 | |
| SCHEMBL1984299 | 0.93 | APP (0.86) | APPGLAGAASULT1A1 | |
| SCHEMBL13806294 | 0.92 | APP (0.85) | APPGLAGAASULT1A1 | |
| SCHEMBL5429982 | 0.88 | APP (0.83) | APPGLAGAASULT1A1 | |
| SCHEMBL2633247 | 0.86 | APP (0.75) | APPGLAGAASULT1A1 | |
| SCHEMBL2192191 | 0.85 | APP (0.72) | APPGLAGAA | |
| SCHEMBL26017584 | 0.84 | APP (0.76) | APPGLAGAASULT1A1 | |
| SCHEMBL23766560 | 0.83 | APP (0.74) | APPGLAGAASULT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400549-A1 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | ACADEMIA SINICA (TW) | 2024-12-05 | — | — | US | disclosed |
| US-10137210-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | The University of Pittsburgh—Of the Commonwealth System of Higher Education (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-01 | — | — | US | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| US-9134328-B2 | Methods of using benzothiazole derivative compounds and compositions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1611115-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | University of Pittsburgh (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050043377-A1 | Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH | 2005-02-24 | — | — | US | disclosed |
| WO-2004083195-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | UNIVERSITY OF PITTSBURGH (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030236391-A1 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH | 2003-12-25 | — | — | US | disclosed |
| EP-1334091-A2 | THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPY OF ALZHEIMER'S DISEASE | UNIVERSITY OF PITTSBURGH (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020133019-A1 | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition | PITTSBURGH, UNIVERSITY OF | 2002-09-19 | — | — | US | disclosed |
| WO-2002016333-A2 | THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPHY OF ALZHEIMER'S DISEASE | UNIVERSITY OF PITTSBURGH (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400549-A1 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | HTT, MAPT, GRN | APP 28/4885GLA 131/4885GAA 23/4885 |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885GLA 180/4885GAA 962/4885 |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885GLA 126/4885GAA 962/4885 |
| US-20020133019-A1 | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition | APP, PSEN2, MAPT | APP 1/4885GLA 148/4885GAA 1121/4885 |
| US-20050043377-A1 | Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition | APP, PSEN2, MAPT | APP 1/4885GLA 189/4885GAA 986/4885 |
| US-20030236391-A1 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | TTR, APP, BACE1 | APP 2/4885GLA 133/4885GAA 1121/4885 |
| US-10137210-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | APP, PSEN2, MAPT | APP 1/4885GLA 180/4885GAA 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.